Monday November 23 2009 | Biotechnology feed | All feeds
|
|
Monday November 23 2009 | Biotechnology feed | All feeds
|
|
|
Targeting host cellular machinery to prevent HIV-1 infection For those aged 25-44, HIV dropped from the leading cause of death in 1995 to third and fifth leading causes of death in 1996 and 1997 respectively. The age-adjusted HIV death rate of 5.9 deaths per 100,000 is the lowest rate since 1987; the first year mortality data were available for the disease. This dramatic reduction in AIDS related deaths has largely been due to the advent of anti-retroviral agents which prolong AIDS-free HIV infection as well as life-expectancy once AIDS has developed. Despite the success of HIV therapies, there is still a demand for molecules with reduced toxicity and susceptibility to drug resistance. Early HIV therapies have targeted viral proteins however approaches now include the cellular machinery as a therapeutic option. One such example is the vacuolar protein-sorting pathway that plays a role in the transport of the retroviral structural precursor (Gag) protein to its budding site on the plasma membrane of infected cells. Drug development activities centering on the identification of molecules able to interfere with this virus:host intertaction could lead to the identification of virus-specific modulators and provide opportunities to design new targeted anti-viral agents. Link to journal abstract:
Interested in collaborating with this group? Contact leaddiscovery@bioportfolio.co.uk LeadDiscovery and BioPortfolio aims to provide reliable, insightful analysis on the biotechnology industry. However, this information is provided "as is" and no representations or warranties either express or implied of completeness, accuracy, or of any other nature are made with respect to this information. This information is neither an offer to sell nor a solicitation to buy the securities of any company. This information contains forward-looking statements, which involve risks and uncertainties which may not be listed. The biotechnology industry is an emerging industry and the securities of the companies mentioned in this report have a very high degree of risk and volatility. For this reason, this information is supplied on the condition that the reader will make his or her own determination as to its suitability for any purpose prior to any use of this information. The employees and officers of LeadDiscovery and BioPortfolio may hold positions in some or all of the stocks discussed in this report. This abstract has been produced by LeadDiscovery Ltd. Founded by life scientists for life scientists we aim to help industry identify cutting edge drug discovery options and academic/biotech institutions maximize the potential of their research. Abstracts strictly reflect the opinion of LeadDiscovery's editorial panel. While all reasonable efforts are made to ensure the accuracy of information provided LeadDiscovery and the publisher BioPortfolio, takes no responsibility for incorrect or misleading information. LeadDiscovery is designed for educational and drug development purposes only and is not intended or designed to offer medical advice or advice of any sort, and must not be used for such purpose. The information provided through LeadDiscovery and BioPortfolio should not be used for diagnosing or treating a health problem or a disease and no reliance should be placed on any information contained in this abstract or elsewhere on LeadDiscovery's and BioPortfolio's website. It is not intended to be a substitute for professional care. If you have or suspect you may have a health problem, you should consult your physician or other health care provider. |
|
|
